about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationEuropean perspective on multiple myeloma treatment strategies in 2014Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaHave splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.A risk prediction score for invasive mold disease in patients with hematological malignanciesCombination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-rPredicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myelomaEuropean perspective on multiple myeloma treatment strategies: update following recent congressesHuman cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma.Proteasome inhibitor bortezomib for the treatment of multiple myeloma.Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Current multiple myeloma treatment strategies with novel agents: a European perspectiveCurrent status of bortezomib in the treatment of multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.Treatment of relapsed and refractory multiple myeloma in the era of novel agents.Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
P50
Q26782868-52A36616-EBE3-4725-B8E7-EF2B0D641FF5Q27002668-67ADB12E-2AB0-4BB5-A5B6-109050BCE4AEQ27005966-1C716192-D7B2-4726-9AF3-5ACF7363CAD6Q30756778-A27D6945-97F7-4C5A-9A94-D46696CF1EA3Q30828090-FA45D6F6-A516-4C40-8D47-2575B9A39427Q33409172-FCE092A2-479D-4C7A-9AB0-487439F54D0EQ33410172-44C721F9-F176-4B10-ACF5-9413CCCC0A0BQ33412804-3962848A-87C4-4AC0-BA1D-31E7A9B64002Q33413142-E1C44643-D752-4946-B43E-15846643ACD2Q33429426-5EDF5A5F-7B77-4D09-97A8-13B393CCA30BQ33558113-8DE24577-EB2B-4708-B950-57D01A110775Q34401962-B6A51EC5-6F39-4166-97A2-37C82FD7DBDEQ34450381-9DB9C23B-2574-444B-9C0B-EDE4DF3EE82EQ34656801-A233F062-1DDE-4C5E-A424-5F093C3A9F8AQ35002777-E54F51B5-4F82-4C8C-B1CA-A2BE19F260A4Q35005712-F8005A46-107C-4F6C-B11F-07977EE2A98BQ35180069-5E821733-C68F-43EB-B190-E81014F25204Q35588325-0596D385-35E8-4635-BB55-34EFA8776908Q35683215-8F49421A-7B23-4712-BB0A-38C5B6268397Q35802414-07E31B10-2351-4BF9-BA1D-E1CE30F9FCD8Q35880375-DCBA6E40-10A0-4094-9BEB-B15031F89B9EQ35989943-BFB875B0-6EF1-4050-8D52-51B847F82ABCQ36045296-2856DD16-D4C9-45EA-B20B-F58407C1E0A5Q36115636-F7C385C9-E113-4CF5-BFAA-0CDC0D3A3BD6Q36115674-1E06DE3D-CFCD-421C-8EB3-3929872B34F8Q36115680-9B1AE3D4-CEB3-4043-9567-7EC7FDC90B4CQ36187756-BDAF7C7D-D62D-4E7C-B154-4376F405A78AQ36523911-AB3F602C-1243-4F25-819B-C849FC1E32B7Q36544560-F90B7535-0CA1-4489-8B75-2D8DD5F155E7Q36708942-3C113015-6E19-44E9-ACE6-C5BC831D3851Q36839385-214F95E3-7DF0-4638-87DB-A68FCA4D7FF6Q36929923-F1559ADA-561E-4E43-A17D-A9049A5F27F3Q36962747-EF1BD560-B4AC-4383-9C66-D8013FB51F83Q37552008-968D2076-029F-4C34-A006-125E9D8A6AACQ37677935-4A90DF1A-35B2-4A8A-A6F4-18841948F4EBQ37738476-984DAEAD-6079-4962-8385-E4C25FEA7723Q37761370-C0CBB35D-8341-44A7-8974-03BD3F912359Q37784220-1E9A469F-2AD6-4B72-83B1-14AFC455EF96Q37791639-53D660B4-ED82-4C1A-9B1E-93148F318062Q37801221-C5931E89-0870-48E0-85C9-63FB4B312D88
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michele Cavo
@ast
Michele Cavo
@en
Michele Cavo
@es
Michele Cavo
@nl
type
label
Michele Cavo
@ast
Michele Cavo
@en
Michele Cavo
@es
Michele Cavo
@nl
prefLabel
Michele Cavo
@ast
Michele Cavo
@en
Michele Cavo
@es
Michele Cavo
@nl
P1006
P214
P1006
P106
P1153
7005399620
P214
P31
P496
0000-0003-4514-3227
P7859
lccn-n88290996